Viamet Pharmaceuticals Appoints Former Novartis Corporation Executive Marc Rudoltz, M.D. as Chief Medical Officer
Published: Nov 03, 2011
MORRISVILLE, N.C.--(BUSINESS WIRE)--Viamet Pharmaceuticals, Inc. announced today the appointment of Marc S. Rudoltz, M.D. to the newly created position of Chief Medical Officer. Dr. Rudoltz will oversee the development of the company’s novel therapies for oncology and infectious disease, including VT-1161 and VT-464. VT-1161 is an orally-administered, small molecule therapy in human clinical studies for the treatment of a range of fungal infections including onychomycosis. VT-464 is an orally-administered, small molecule therapy for the treatment of castration-refractory prostate cancer.